A2 gene of Old World cutaneous Leishmania is a single highly conserved functional gene

BMC Infectious Diseases

Volumn 5, Issue , 2005, Pages

  Garin, Yves J F ^a   Meneceur, Pascale ^a   Pratlong, Francine ^b   Dedet, Jean Pierre ^b   Derouin, Francis ^a   Lorenzo, Frédéric ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; MESSENGER RNA; PROTOZOAL DNA; PROTOZOAL PROTEIN;

5' UNTRANSLATED REGION; ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE FUNCTION; GENE SEQUENCE; GENETIC CONSERVATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HYPOTHESIS; IMMUNOGENICITY; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; NONHUMAN; NUCLEOTIDE REPEAT; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTOZOAL GENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SKIN LEISHMANIASIS; SPECIES DIFFERENCE; STRAIN DIFFERENCE;

EID: 25444482154     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-5-18     Document Type: Article

References (24)

1. Zhang WW, Mendez S, Ghosh A, Myler P, Ivens A, Clos J, Sacks DL, Matlashewski G: Comparison of the A2 gene locus in L. dono-vani and L. major and its control over cutaneous infection. J Biol Chem 2003, 278:35508-35515.
2. WHO: The leishmaniases and Leishmania/HIV co-infections. WHO Fact Sheet No 116 2000.
3. WHO: Reducing risks, promoting healthy life. The World Health Report 2002, WHO, Geneva, Switzerland. The World Health Report 2002 2002.
4. Blackwell JM: Genetic susceptibility to leishmanial infections: studies in mice and man. Parasitology 1996, 112 Suppl:S67-S74.
5. Gradoni L, Gramiccia M: Leishmania infantum tropism: strain genotype or host immune status ? Parasitol Today 1994, 10:264-267.
6. Kubar J, Marty P, Lelievre A, Quaranta JF, Staccini P, Caroli-Bosc C, Le Fichoux Y: Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts. AIDS 1998, 12:2147-2153.
7. Garin YJ, Sulahian A, Pratlong F, Meneceur P, Gangneux JP, Prina E, Dedet JP, Derouin F: Virulence of Leishmania infantum is expressed as a clonal and dominant phenotype in experimental infections. Infect Immun 2001, 69:7365-7373.
8. Honore S, Garin YJ, Sulahian A, Gangneux JP, Derouin F: Influence of the host and parasite strain in a mouse model of visceral Leishmania infantum infection. FEMS Immunol Med Microbiol 1998, 21:231-239.
9. Matlashewski G: Leishmania infection and virulence. Med Microbiol Immunol (Berl) 2001, 190:37-42.
10. Charest H, Matlashewski G: Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigote-stage-specific gene. Mol Cell Biol 1994, 14:2975-2984.
11. Zhang WW, Matlashewski G: Characterization of the A2-A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection. Mol Microbiol 2001, 39:935-948.
12. Zhang WW, Matlashewski G: Loss of virulence in Leishmania donovani deficient in an amastigote-specific protein, A2. Proc Natl Acad Sci U S A 1997, 94:8807-8811.
13. Ghosh A, Zhang WW, Matlashewski G: Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 2001, 20:59-66.
14. Ghosh A, Labrecque S, Matlashewski G: Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response. Vaccine 2001, 19:3169-3178.
15. Coelho EA, Tavares CA, Carvalho FA, Chaves KF, Teixeira KN, Rodrigues RC, Charest H, Matlashewski G, Gazzinelli RT, Fernandes AP: Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect Immun 2003, 71:3988-3994.
16. Ghedin E, Zhang WW, Charest H, Sundar S, Kenney RT, Matlashewski G: Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis. Clin Diagn Lab Immunol 1997, 4:530-535.
17. Carvalho FA, Charest H, Tavares CA, Matlashewski G, Valente EP, Rabello A, Gazzinelli RT, Fernandes AP: Diagnosis of American visceral leishmaniasis in humans and dogs using the recombinant Leishmania donovani A2 antigen. Diagn Microbiol Infect Dis 2002, 43:289-295.
18. WHO: Control of the leishmaniases. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1990, 793:1-158.
19. Garin YJ, Meneceur P, Sulahian A, Derouin F: Microplate method for obtaining Leishmania clonal populations. J Parasitol 2002, 88:803-804.
20. Berens RL, Marr JJ: An easily prepared defined medium for cultivation of Leishmania donovani promastigotes. J Parasitol 1978, 64:160.
21. Zhang WW, Charest H, Ghedin E, Matlashewski G: Identification and overexpression of the A2 amastigote-specific protein in Leishmania donovani. Mol Biochem Parasitol 1996, 78:79-90.
22. Ghedin E, Charest H, Matlashewski G: A2rel: a constitutively expressed Leishmania gene linked to an amastigote-stage-specific gene. Mol Biochem Parasitol 1998, 93:23-29.
23. Pacheco RS, Grimaldi GJ, Momen H, Morel CM: Population heterogeneity among clones of New World Leishmania species. Parasitology 1990, 100 Pt 3:393-398.
24. Cupolillo E, Grimaldi GJ, Momen H: Genetic diversity among Leishmania (Viannia) parasites. Ann Trop Med Parasitol 1997, 91:617-626.